Full-Time

Biostatistics Associate Director

Confirmed live in the last 24 hours

Vertex Pharmaceuticals

Vertex Pharmaceuticals

1,001-5,000 employees

Develops medicines for serious diseases

Compensation Overview

$164.8k - $247.2k/yr

+ Bonus + Equity Awards

Senior

Company Does Not Provide H1B Sponsorship

Boston, MA, USA

Relocation Assistance is available.

Category
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
SAS
R
Requirements
  • In-depth competence with SAS and R statistical software
  • In-depth understanding of advanced statistical methods used in drug development
  • Ability to show critical thinking with logical problem-solving
  • Excellent written and verbal communication skills
  • Excels in a team environment
  • Collaborates well with non-statisticians
  • NDA/MAA experience and direct dealings with USA/European regulators
  • Ph. D. in Statistics or Biostatistics
  • Typically requires 7 years of experience with a Ph.D.
Responsibilities
  • Conducts all scientific and operational statistical work for multiple clinical trials, observational studies, or real world data (RWD) investigations.
  • Leads biostatistics projects or major components of a project including work allocation and review.
  • May include presentation to the Peer Protocol Review Committee (PPRC) or other internal senior review boards.
  • Possesses an advanced and in-depth understanding of modern drug discovery and development processes.
  • Represents Biostatistics as a member of cross functional teams, providing input and specialized technical guidance to elicit meaningful and/or productive outcomes.
  • Authors study Statistical Analysis Plans (SAPs), including table, figure, and listing (TFL) shells. Develops Cross-functional Data Review (xFDR) plan, Key Reports Memo (KRM), and Data Dissemination Plan (DDP) in order to facilitate the review, summary, and dissemination of key study data/results.
  • Collaborates with statistical programming and other functions to ensure timely delivery of TFLs with high quality.
  • Contributes to clinical study reports (CSRs) and related processes, authoring or co-authoring methodological or study-related publications and posters.
  • Provides input into programming specifications and review.
  • Contributes to external interactions with regulators, payers, review boards, etc.
  • Authors or co-authors methodological or study-related publications and posters.
  • Determines and implements design and analysis methods at the study or project level and participates in Statistical Review Forum (SRF) discussions of studies assigned to others.
  • Contributes to departmental working group efforts on various advanced technical and operational issues.
  • Independently undertakes new and complex issues.
  • Completes assigned work in a resourceful, self-sufficient manner, often conceptualizing alternative approaches to achieve desired results.
  • Develops breadth of knowledge across related disciplines with a drug developer mindset.
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, focusing on conditions like cystic fibrosis. The company conducts extensive research and development to create new drugs, often collaborating with other biotech firms to enhance its therapeutic offerings. One of its notable products is ivacaftor, which has shown effectiveness in treating cystic fibrosis. Vertex differentiates itself from competitors through its commitment to scientific innovation and strategic partnerships that expand its research capabilities. The goal of Vertex Pharmaceuticals is to improve the quality of life for patients with severe and life-threatening conditions by bringing effective treatments to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Simplify Jobs

Simplify's Take

What believers are saying

  • Vertex's EU approval expands its cystic fibrosis treatment market.
  • Partnerships with Arbor and Orna enhance Vertex's gene therapy capabilities.
  • Increased rare disease research funding supports Vertex's R&D efforts.

What critics are saying

  • Competition in cystic fibrosis treatments threatens Vertex's market share.
  • High R&D costs and trial delays could strain Vertex's finances.
  • Regulatory challenges may limit Vertex's drug market expansion.

What makes Vertex Pharmaceuticals unique

  • Vertex focuses on transformative medicines for serious diseases, like cystic fibrosis.
  • The company invests heavily in R&D and strategic biotech partnerships.
  • Vertex's innovative cell and gene therapies set it apart in the biotech industry.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Company News

BioSpace
Apr 14th, 2025
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis

Vertex researcher, Paul Negulescu Ph.D., receives the 2025 Canada Gairdner International Award for pioneering Research and discovery of medicines for Cystic Fibrosis.

Biz Owner Daily
Apr 7th, 2025
EU Approves Expanded Label for Vertex Pharmaceuticals' Cystic Fibrosis Treatment

Vertex Pharmaceuticals has received approval from the European Union to broaden the label for its cystic fibrosis treatment.

Slater Sentinel
Mar 23rd, 2025
Stevens Capital Management LP Makes New $829,000 Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Stevens Capital Management LP makes new $829,000 investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Investing.com
Mar 20th, 2025
BMO maintains Vertex stock Market Perform rating and $41 target

The reaffirmation of the rating and target came after Vertex held its first analyst day since its initial public offering in 2020.

Stat News
Mar 18th, 2025
Genetics expert is first NIH director to leave under Trump

He will be replaced on an interim basis by Director Ian Smith, a former Vertex Pharmaceuticals executive.